Menu
Back to Journals » Biologics: Targets and Therapy » Volume 15 » default
Biologics: Targets and Therapy
ISSN: 1177-5491
- View all (502)
- Volume 18, 2024 (6)
- Volume 17, 2023 (17)
- Volume 16, 2022 (18)
- Volume 15, 2021 (40)
- Volume 14, 2020 (13)
- Volume 13, 2019 (17)
- Volume 12, 2018 (19)
- Volume 11, 2017 (14)
- Volume 10, 2016 (18)
- Volume 9, 2015 (17)
- Volume 8, 2014 (27)
- Volume 7, 2013 (28)
- Volume 6, 2012 (46)
- Volume 5, 2011 (9)
- Volume 4, 2010 (31)
- Volume 3, 2009 (45)
- Volume 2, 2008 (89)
- Volume 1, 2007 (48)
Archive: Volume 15, 2021
Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population
Berman J, Furer V, Berman M, Isakov O, Zisman D, Haddad A, Elkayam O
Biologics: Targets and Therapy 2021, 15:463-470
Published Date: 18 November 2021
State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer
Basile D, Simionato F, Cappetta A, Garattini SK, Roviello G, Aprile G
Biologics: Targets and Therapy 2021, 15:451-462
Published Date: 3 November 2021
Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
Rizzo M, Giannatempo P, Porta C
Biologics: Targets and Therapy 2021, 15:441-450
Published Date: 1 November 2021
Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients
Santos-Moreno P, Martinez S, Ibatá L, Villarreal L, Rivero M, Rojas-Villarraga A
Biologics: Targets and Therapy 2021, 15:433-440
Published Date: 22 October 2021
Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia
Abuasab T, Rowe J, Tvito A
Biologics: Targets and Therapy 2021, 15:419-431
Published Date: 18 October 2021
Immunotherapeutic Advances for NSCLC
Massafra M, Passalacqua MI, Gebbia V, Macrì P, Lazzari C, Gregorc V, Buda C, Altavilla G, Santarpia M
Biologics: Targets and Therapy 2021, 15:399-417
Published Date: 8 October 2021
Stem Cell Therapy for Burns: Story so Far
Abdul Kareem N, Aijaz A, Jeschke MG
Biologics: Targets and Therapy 2021, 15:379-397
Published Date: 31 August 2021
Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection
Madani A, Almuhaideb Q
Biologics: Targets and Therapy 2021, 15:375-378
Published Date: 1 September 2021
An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease
Cazzola M, Ora J, Cavalli F, Rogliani P, Matera MG
Biologics: Targets and Therapy 2021, 15:363-374
Published Date: 27 August 2021
Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing
Mengstie MA, Wondimu BZ
Biologics: Targets and Therapy 2021, 15:353-361
Published Date: 21 August 2021
Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
Findeisen KE, Sewell J, Ostor AJK
Biologics: Targets and Therapy 2021, 15:343-352
Published Date: 12 August 2021
HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma
Xu Y, Zhijie H, Yu X, Li Z, Zheng L, Xu J
Biologics: Targets and Therapy 2021, 15:329-341
Published Date: 13 August 2021
Infliximab in Combination with Low-Dose Acitretin in Generalized Pustular Psoriasis: A Report of Two Cases and Review of the Literature
Kołt-Kamińska M, Żychowska M, Reich A
Biologics: Targets and Therapy 2021, 15:317-327
Published Date: 7 August 2021
View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson’s Disease: Are We on the Right Track?
Müller T
Biologics: Targets and Therapy 2021, 15:307-316
Published Date: 29 July 2021
Stem Cell Therapy for Retinal Degeneration: The Evidence to Date
Sharma A, Jaganathan BG
Biologics: Targets and Therapy 2021, 15:299-306
Published Date: 27 July 2021
Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval
Kurdi M, Butt NS, Baeesa S, Kuerban A, Maghrabi Y, Bardeesi A, Saeedi R, Alghamdi BS, Lary AI, Mohamed F, Hakamy S
Biologics: Targets and Therapy 2021, 15:289-297
Published Date: 24 July 2021
High Body Mass Index is Associated with Shorter Retention of Tumor Necrosis Factor-Alpha Blocker Treatment in Rheumatoid Arthritis
Elalouf O, Lidar M, Reitblat T, Zisman D, Balbir-Gurman A, Hakakian O, Mashiach T, Almog R, Elkayam O
Biologics: Targets and Therapy 2021, 15:279-287
Published Date: 20 July 2021
The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy
Hamilton G, Plangger A
Biologics: Targets and Therapy 2021, 15:265-277
Published Date: 7 July 2021
Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review
Elsbernd PM, Carter JL
Biologics: Targets and Therapy 2021, 15:255-263
Published Date: 30 June 2021
Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules
Bellinato F, Gisondi P, Girolomoni G
Biologics: Targets and Therapy 2021, 15:247-253
Published Date: 29 June 2021
An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn’s Disease
Chien TH, Puig A, Khuong T, Kouhkamari MH, Che S, Huang THW
Biologics: Targets and Therapy 2021, 15:237-245
Published Date: 16 June 2021
Recent Advances in the Treatment of Hemophilia: A Review
Marchesini E, Morfini M, Valentino L
Biologics: Targets and Therapy 2021, 15:221-235
Published Date: 15 June 2021
Monoclonal Antibody Therapies for High Risk Neuroblastoma
Furman WL
Biologics: Targets and Therapy 2021, 15:205-219
Published Date: 9 June 2021
Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer
Tiruneh G/Medhin M, Chekol Abebe E, Sisay T, Berhane N, Bekele Snr T, Asmamaw Dejenie T
Biologics: Targets and Therapy 2021, 15:199-204
Published Date: 31 May 2021
How Can We Engineer CAR T Cells to Overcome Resistance?
Glover M, Avraamides S, Maher J
Biologics: Targets and Therapy 2021, 15:175-198
Published Date: 19 May 2021
Antibody Therapies for Large B-Cell Lymphoma
Novo M, Santambrogio E, Frascione PMM, Rota-Scalabrini D, Vitolo U
Biologics: Targets and Therapy 2021, 15:153-174
Published Date: 18 May 2021
Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target
Chekol Abebe E, Mengie Ayele T, Tilahun Muche Z, Asmamaw Dejenie T
Biologics: Targets and Therapy 2021, 15:143-152
Published Date: 6 May 2021
Biological Therapies in Children and Adolescents with Severe Uncontrolled Asthma: A Practical Review
Votto M, De Filippo M, Licari A, Marseglia A, De Amici M, Marseglia GL
Biologics: Targets and Therapy 2021, 15:133-142
Published Date: 5 May 2021
Baculoviruses in Gene Therapy and Personalized Medicine
Schaly S, Ghebretatios M, Prakash S
Biologics: Targets and Therapy 2021, 15:115-132
Published Date: 28 April 2021
Acrodermatitis Continua of Hallopeau Evolving into Generalized Pustular Psoriasis Following COVID‐19: A Case Report of a Successful Treatment with Infliximab in Combination with Acitretin
Samotij D, Gawron E, Szczęch J, Ostańska E, Reich A
Biologics: Targets and Therapy 2021, 15:107-113
Published Date: 27 April 2021
Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
Hawkins ER, D'Souza RR, Klampatsa A
Biologics: Targets and Therapy 2021, 15:95-105
Published Date: 14 April 2021
Virus Neutralization by Human Intravenous Immunoglobulin Against Influenza Virus Subtypes A/H5 and A/H7
Kubota-Koketsu R, Yunoki M, Okuno Y, Ikuta K
Biologics: Targets and Therapy 2021, 15:87-94
Published Date: 13 April 2021
Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon
O'Donnell KL, Marzi A
Biologics: Targets and Therapy 2021, 15:79-86
Published Date: 18 March 2021
The Current Status of Gene Therapy for the Treatment of Cancer
Belete TM
Biologics: Targets and Therapy 2021, 15:67-77
Published Date: 18 March 2021
Glomerulonephritis in Two Patients with SpA Treated with TNF-α Blockers and a Review of the Literature
Bounia CA, Theodoropoulou EN, Liossis SNC
Biologics: Targets and Therapy 2021, 15:61-66
Published Date: 17 March 2021
Autologous Hematopoietic Stem Cell Transplantation (AHSCT): An Evolving Treatment Avenue in Multiple Sclerosis
Mohammadi R, Aryan A, Omrani MD, Ghaderian SMH, Fazeli Z
Biologics: Targets and Therapy 2021, 15:53-59
Published Date: 2 March 2021
Biologic Treatments of Psoriasis: An Update for the Clinician
Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, Koo J
Biologics: Targets and Therapy 2021, 15:39-51
Published Date: 16 February 2021
Convalescent Plasma for the Treatment of Severe COVID-19
Franchini M, Liumbruno GM
Biologics: Targets and Therapy 2021, 15:31-38
Published Date: 4 February 2021
Biologic Therapies for Giant Cell Arteritis
Harrington R, Al Nokhatha SA, Conway R
Biologics: Targets and Therapy 2021, 15:17-29
Published Date: 6 January 2021
Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
Fitzgerald T, Melsheimer R, Lafeuille MH, Lefebvre P, Morrison L, Woodruff K, Lin I, Emond B
Biologics: Targets and Therapy 2021, 15:1-15
Published Date: 6 January 2021